ONCAlert | Upfront Therapy for mRCC
Videos  >  

The Rationale for the Phase I TRANSCEND NHL 001 Trial

Jeremy S. Abramson, MD
Published Online:6:00 PM, Thu February 13, 2020


Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the rationale for phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory large B-cell lymphoma, which were presented at the 2019 American Society of Hematology Annual Meeting.

TRANSCEND-NHL 001 was launched to serve an unmet medical need for new treatment options in this patient population. Conventional therapies have a low single-agent response rate, no chance of cure, and median overall survival of 6 month or less in these patient. The hope was that liso-cel would improve outcomes and quality of life in these patients, says Abramson.

For more about the TRANCEND-NHL 001 trial https://www.targetedonc.com/news/fda-grant-priority-review-to-lisocel-in-relapsedrefractory-large-bcell-lymphoma
 
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.